LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Akcijų sąrašas・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

32.49 0.43

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.54

Max

32.71

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.6M -79M
Pardavimai	-60K 15K
Pelnas, tenkantis vienai akcijai	-1.18
Pelno marža	-524,566.667
Darbuotojai	198
EBITDA	-3M -84M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+74.5% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-38M 2.5B
Ankstesnė atidarymo kaina	32.06
Ankstesnė uždarymo kaina	32.49

Naujienos nuotaikos

By Acuity

50%

162 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

18.91 / 20.63 Palaikymas ir pasipriešinimas

Celldex Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-13 22:54; UTC

Uždarbis

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

2026-05-13 23:51; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-13 23:51; UTC

Rinkos pokalbiai

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

2026-05-13 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-13 23:17; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-13 23:16; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

2026-05-13 23:15; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

2026-05-13 23:14; UTC

Uždarbis

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

2026-05-13 23:02; UTC

Rinkos pokalbiai

Uždarbis

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

2026-05-13 22:59; UTC

Rinkos pokalbiai

Uždarbis

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

2026-05-13 22:24; UTC

Uždarbis

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Organic Revenue Growth 25%>XRO.AU

2026-05-13 22:23; UTC

Uždarbis

Xero FY International Revenue Growth 47%>XRO.AU

2026-05-13 22:22; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

2026-05-13 22:19; UTC

Uždarbis

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

2026-05-13 22:18; UTC

Uždarbis

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

2026-05-13 22:16; UTC

Uždarbis

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

2026-05-13 22:15; UTC

Uždarbis

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

2026-05-13 22:13; UTC

Uždarbis

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

2026-05-13 22:12; UTC

Uždarbis

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

2026-05-13 22:11; UTC

Uždarbis

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero Did Not Declare a Dividend>XRO.AU

2026-05-13 22:10; UTC

Uždarbis

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

2026-05-13 22:09; UTC

Uždarbis

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

2026-05-13 22:00; UTC

Uždarbis

Cisco to Shed Jobs for All-In AI Push -- Update

2026-05-13 21:11; UTC

Uždarbis

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Celldex Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

74.5% į viršų

12 mėnesių prognozė

Vidutinis 56.73 USD 74.5%

Aukščiausias 90 USD

Žemiausias 38 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Celldex Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

Pirkti

Laikyti

Parduoti

Remiantis 12 analitikų, pateikusių Celldex Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

18.91 / 20.63Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

162 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.